Abstract:Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis. Methods: In order to improve the understanding on the relation between host immune response and disease course, we have studied the differences in the cellular (monocytes, CD8+ T and NK cells) and soluble (cytokines, chemokines and immunoregulatory ligands) immune response in blood between Healthy Donors (HD), COVID19 and a group of patients with non-COVID19 respiratory tract infections (NON-COV-RTI). In addition, the immune response profile has been analyzed in COVID19 patients according to disease severity. Results: In comparison to HDs and patients with NON-COV-RTI, COVID19 patients show a heterogeneous immune response with the presence of both activated and exhausted CD8+ T and NK cells characterised by the expression of the immune checkpoint LAG3 and the presence of the adaptive NK cell subset. An increased frequency of adaptive NK cells and a reduction of NK cells expressing the activating receptors NKp30 and NKp46 correlated with disease severity. Although both activated and exhausted NK cells expressing LAG3 were increased in moderate/severe cases, unsupervised cell clustering analyses revealed a more complex scenario with single NK cells expressing more than one immune checkpoint (PD1, TIM3 and/or LAG3). A general increased level of inflammatory cytokines and chemokines was found in COVID19 patients, some of which like IL18, IL1RA, IL36B and IL31, IL2, IFNα and TNFα, CXCL10, CCL2 and CCL8 were able to differentiate between COVID19 and NON-COV-RTI and correlated with bad prognosis (IL2, TNFα, IL1RA, CCL2, CXCL10 and CXCL9). Notably, we found that soluble NKG2D ligands from the MIC and ULBPs families were increased in COVID19 compared to NON-COV-RTI and correlated with disease severity. Conclusions: Our results provide a detailed comprehensive analysis of the presence of activated and exhausted CD8+T, NK and monocyte cell subsets as well as extracellular inflammatory factors beyond cytokines/chemokines, specifically associated to COVID19. Importantly, multivariate analysis including clinical, demographical and immunological experimental variables have allowed us to reveal specific immune signatures to i) differentiate COVID19 from other infections and ii) predict disease severity and the risk of death.

Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients

Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19

Lipid Alternations in the Plasma of COVID-19 Patients with Various Clinical Presentations.

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients

Polyunsaturated fatty acid-derived lipid mediator networks characterize COVID-19 severity and risk for critical illness

Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Characterization of the Inflammatory Response to Severe COVID-19 Illness

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

A systematic meta-analysis of immune signatures in patients with COVID-19

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

Acetylcholine, Fatty Acids, and Lipid Mediators Are Linked to COVID-19 Severity

Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Phospholipid Remodeling and Its Derivatives Are Associated with COVID-19 Severity

Lipid metabolism changes in patients with severe COVID-19

Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis

Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes

An inflammatory cytokine signature predicts COVID-19 severity and survival